Brief: Ampio Updates Regulatory Status For Ampion
06/03/2019 13:40
March 6 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO UPDATES REGULATORY STATUS FOR AMPION
* AMPIO PHARMACEUTICALS - FDA PROVIDED GUIDANCE THAT CO
SHOULD
COMPLETE AN ADDITIONAL TRIAL OF KELLGREN LAWRENCE GRADE 4
OSTEOARTHRITIS OF KNEE PATIENTS
* AMPIO PHARMA - ADDITIONAL TRIAL OF KL 4 OAK PATIENTS
SHOULD BE
WITH CONCURRENT CONTROLS THAT WOULD BE CARRIED OUT UNDER SPECIAL
PROTOCOL ASSESSMENT
Source text for Eikon: ID:nPn27WVqPa
Further company coverage: AMPE.A
(((Reuters.Briefs@thomsonreuters.com);;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank